Share Your Story
“My father's peaceful death came as a result of his family's commitment to see that he was well-cared for at home. The hospice professionals were with us every step of the way and helped us cope. Caring for my father, even with the help of professionals, was the most difficult thing I have ever done. My sister and I devoted ourselves to his care for those 29 days, but neither of us has any regrets. We know we did the right thing.”
Many families and friends have powerful stories to share.
Tell your lymphoma story in 500 wds for LA Times's "MY TURN" column.
My Turn is a forum for readers to recount an experience related to health or fitness. Submissions should be no more than 500 words. They are subject to editing and condensation and become the property of The Times. Please e-mail [email protected]. Although they read every essay, they can't respond to every writer.
More Articles
More Articles
Amazon.com is pleased to have the Lymphoma Information Network in the family of Amazon.com associates. We've agreed to ship items...
The question ought to be what are myelodysplastic syndromes (MDS), since this is a group of similar blood and bone marrow diseases that...
Merkel Cell Carcinoma (MCC) is a very rare and aggressive skin cancer that usually develops when a person is in his or her 70s. It is...
At some point, the Seattle biotech company Cell Therapeutics Inc (CTI) should earn an entry in the Guinness Book of World Records for utter and...
Site Beginnings
This site was started as Lymphoma Resource Page(s) in 1994. The site was designed to collect lymphoma...
Three papers appearing in the journal Blood and pointing towards a regulator-suppressor pill could offer hope to blood cancer...
The US Food and Drug Administration (FDA) has granted a third so-called Breakthrough Therapy Designation for the investigational oral...
The US Food and Drug Administration today has approved an expanded use of Imbruvica (ibrutinib) in patients with...
The U.S. Food and Drug Administration has announced that it has granted "Breakthrough Therapy Designation" for the investigational agent...
According to a new study published in the Proceedings of the National Academy of Sciences, a team from the University of California, San...
Pharmacyclics has announced that the company has submitted a New Drug Application (NDA) to the US Food and Drug Administration (FDA) for...
New research suggests that frontline radioimmunotherapy...
Gilead Sciences has announced results of the company's Phase II study of its investigational compound idelalisib, an oral inhibitor of...
